CN1856490A - 苯并咪唑、苯并噻唑和苯并噁唑衍生物及其作为lta4h调节剂的应用 - Google Patents

苯并咪唑、苯并噻唑和苯并噁唑衍生物及其作为lta4h调节剂的应用 Download PDF

Info

Publication number
CN1856490A
CN1856490A CNA2004800279067A CN200480027906A CN1856490A CN 1856490 A CN1856490 A CN 1856490A CN A2004800279067 A CNA2004800279067 A CN A2004800279067A CN 200480027906 A CN200480027906 A CN 200480027906A CN 1856490 A CN1856490 A CN 1856490A
Authority
CN
China
Prior art keywords
benzothiazole
base
benzyl
alkyl
oxygen base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800279067A
Other languages
English (en)
Chinese (zh)
Inventor
F·U·阿克斯
S·D·贝姆贝内克
C·R·布特勒
J·P·爱德华兹
A·M·福里
C·A·格里斯
B·M·萨瓦尔
K·L·泰斯
J·魏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN1856490A publication Critical patent/CN1856490A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Materials Engineering (AREA)
  • Biomedical Technology (AREA)
  • Structural Engineering (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNA2004800279067A 2003-07-28 2004-07-27 苯并咪唑、苯并噻唑和苯并噁唑衍生物及其作为lta4h调节剂的应用 Pending CN1856490A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49071003P 2003-07-28 2003-07-28
US60/490,710 2003-07-28

Publications (1)

Publication Number Publication Date
CN1856490A true CN1856490A (zh) 2006-11-01

Family

ID=34115427

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2004800279067A Pending CN1856490A (zh) 2003-07-28 2004-07-27 苯并咪唑、苯并噻唑和苯并噁唑衍生物及其作为lta4h调节剂的应用
CN200480028138A Expired - Fee Related CN100591679C (zh) 2003-07-28 2004-07-27 苯并咪唑、苯并噻唑和苯并唑衍生物及其作为lta4h调节剂的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200480028138A Expired - Fee Related CN100591679C (zh) 2003-07-28 2004-07-27 苯并咪唑、苯并噻唑和苯并唑衍生物及其作为lta4h调节剂的应用

Country Status (28)

Country Link
US (2) US20050043378A1 (enExample)
EP (2) EP1660491B1 (enExample)
JP (2) JP2007500703A (enExample)
KR (2) KR20060054408A (enExample)
CN (2) CN1856490A (enExample)
AR (2) AR045729A1 (enExample)
AT (2) ATE403654T1 (enExample)
AU (2) AU2004261628B2 (enExample)
BR (2) BRPI0413072A (enExample)
CA (2) CA2534228A1 (enExample)
CY (1) CY1108560T1 (enExample)
DE (2) DE602004016002D1 (enExample)
DK (2) DK1660492T3 (enExample)
ES (2) ES2311858T3 (enExample)
HR (2) HRP20060041B1 (enExample)
IL (1) IL173372A (enExample)
MY (1) MY145080A (enExample)
NO (2) NO20060771L (enExample)
NZ (2) NZ544938A (enExample)
PL (2) PL1660492T3 (enExample)
PT (2) PT1660491E (enExample)
RU (2) RU2359970C2 (enExample)
SG (2) SG129449A1 (enExample)
SI (2) SI1660492T1 (enExample)
TW (2) TW200520756A (enExample)
UA (2) UA87986C2 (enExample)
WO (2) WO2005012296A1 (enExample)
ZA (2) ZA200601716B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459251A (zh) * 2009-05-14 2012-05-16 詹森药业有限公司 作为白三烯a4水解酶的调节剂的具有两个稠合双环杂芳基部分的化合物
CN101969951B (zh) * 2007-11-16 2012-10-31 雅培制药有限公司 化合物在制备治疗关节炎的药物中的方法
CN107663192A (zh) * 2017-11-03 2018-02-06 梯尔希（南京）药物研发有限公司 一种雷贝拉唑杂质的制备方法
CN113735798A (zh) * 2021-09-27 2021-12-03 安徽美致诚药业有限公司 一种盐酸罗沙替丁醋酸酯的制备方法

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1660492T1 (sl) * 2003-07-28 2009-02-28 Janssen Pharmaceutica Nv Benzimidazolni, benztiazolni in benzoksazolni derivati in njihova uporaba kot modulatorji LTA4H
JP2008536825A (ja) * 2005-03-31 2008-09-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ フェニルおよびピリジルｌｔａ４ｈモジュレータ
PL1877379T3 (pl) 2005-04-13 2013-06-28 Astex Therapeutics Ltd Pochodne hydroksybenzamidu i ich wykorzystanie, jako inhibitorów hsp90
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
ES2359431T3 (es) * 2005-09-02 2011-05-23 F. Hoffmann-La Roche Ag Derivados de benzooxazol, oxazolopiridina, benzotiazol y tiazolopiridina.
CA2623348A1 (en) * 2005-09-21 2007-04-12 Decode Genetics Ehf Biaryl substituted heterocycle inhibitors of lta4h for treating inflammation
EP1968961A2 (en) * 2005-12-21 2008-09-17 Decode Genetics EHF Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
CA2634699A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
US7576102B2 (en) 2005-12-21 2009-08-18 Decode Genetics Ehf Biaryl substituted nitrogen containing heterocycle inhibitors of LTA4H for treating inflammation
DK1976828T3 (en) 2005-12-29 2017-03-06 Celtaxsys Inc DIAMINE DERIVATIVES AS INhibitors of Leukotriene A4 HYDROLASE
JP2009525269A (ja) * 2006-01-30 2009-07-09 ユーロ−セルティーク エス．エイ． カルシウムチャネルブロッカーとしての環状尿素化合物
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US7951829B2 (en) * 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
AU2007260356B2 (en) * 2006-06-16 2013-01-24 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
US8115005B2 (en) 2006-08-04 2012-02-14 Decode Genetics Ehf. Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation
EP2066800A2 (en) 2006-08-04 2009-06-10 Decode Genetics EHF Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation
US7728032B2 (en) * 2006-08-04 2010-06-01 Decode Genetics Ehf Phenoxymethylalkyne inhibitors of LTA4H for treating inflammation
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
US8277807B2 (en) 2006-10-12 2012-10-02 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044054A2 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Hydroxy-substituted benzoic acid amide compounds for use in therapy
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof
BRPI0808775A2 (pt) * 2007-03-08 2017-05-30 Irm Llc compostos e composições como moduladores de atividade de gpr119
WO2008120710A1 (ja) * 2007-03-30 2008-10-09 Panasonic Electric Works Co., Ltd. 活動強度計
AR069126A1 (es) * 2007-10-31 2009-12-30 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
ES2400875T3 (es) 2008-04-11 2013-04-15 Janssen Pharmaceutica N.V. Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno A4 hidrolasa
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
HRP20141038T2 (hr) 2008-04-28 2015-07-03 Janssen Pharmaceutica N.V. Benzoimidazoli kao inhibitori prolil hidroksilaze
CN102442962A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-烷基四氮唑的生产方法
CN102442961A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-甲基四氮唑的生产方法
MX368157B (es) 2011-10-25 2019-09-20 Janssen Pharmaceutica Nv Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.
JP6527851B2 (ja) 2013-03-12 2019-06-05 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素を阻害する方法
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
EP2970309A4 (en) 2013-03-14 2016-11-09 Celtaxsys Inc INHIBITORS OF LEUCOTRIENE A4 HYDROLASE
MX2015011676A (es) 2013-03-14 2016-04-25 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
DK3083562T3 (da) * 2013-12-17 2017-11-13 Lilly Co Eli Cykliske phenoxyethylaminderivater og deres aktivitet som EP4-receptormodulatorer
WO2016100823A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
EP3233077A4 (en) 2014-12-19 2018-08-08 The Broad Institute Inc. Dopamine d2 receptor ligands
AU2016276316B2 (en) 2015-06-09 2020-01-23 Abbvie Inc. Nuclear receptor modulators
CN110088292A (zh) 2016-12-21 2019-08-02 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的方法
KR102390246B1 (ko) 2016-12-21 2022-04-22 에프. 호프만-라 로슈 아게 항체의 시험관내 글리코조작에 있어서의 효소의 재사용
AU2019278935B2 (en) 2018-05-31 2025-02-13 Celltaxis, Llc Method of reducing pulmonary exacerbations in respiratory disease patients
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
SG11202107080VA (en) * 2019-01-11 2021-07-29 Naegis Pharmaceuticals Inc Leukotriene synthesis inhibitors
CN110026557B (zh) * 2019-05-28 2021-08-27 南方科技大学 一种混合固体颗粒重熔的直写装置及成型方法
CA3202720A1 (en) * 2020-11-19 2022-05-27 Telo Therapeutics, Inc. Small molecule compounds and compositions
US11932630B2 (en) * 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CN113683491A (zh) * 2021-09-01 2021-11-23 王传良 一种4-(2-溴乙基)苯酚的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873346A (en) 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
DK171349B1 (da) * 1986-11-14 1996-09-16 Hoffmann La Roche Tetrahydronaphthalenderivater, fremgangsmåde til fremstilling deraf, lægemidler indeholdende forbindelserne samt anvendelse af forbindelserne til fremstilling af lægemidler
IL90337A0 (en) * 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
IT1240598B (it) * 1990-03-13 1993-12-17 Mini Ricerca Scient Tecnolog Derivati amminici ad azione antifungina
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5925654A (en) * 1997-03-12 1999-07-20 G.D. Searle & Co. LTA4 , hydrolase inhibitors
HUP0100156A3 (en) * 1998-02-25 2002-12-28 Genetics Inst Inc Cambridge Indole derivatives as inhibitors of phospholipase a2 and use of them for producing pharmaceutical compositions
US6514964B1 (en) * 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US20040110757A1 (en) * 2002-03-21 2004-06-10 Thomas Arrhenius Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
SI1660492T1 (sl) * 2003-07-28 2009-02-28 Janssen Pharmaceutica Nv Benzimidazolni, benztiazolni in benzoksazolni derivati in njihova uporaba kot modulatorji LTA4H
US7541466B2 (en) * 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
MX2007011273A (es) * 2005-03-16 2007-11-08 Meda Pharma Gmbh & Co Kg La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101969951B (zh) * 2007-11-16 2012-10-31 雅培制药有限公司 化合物在制备治疗关节炎的药物中的方法
CN102459251A (zh) * 2009-05-14 2012-05-16 詹森药业有限公司 作为白三烯a4水解酶的调节剂的具有两个稠合双环杂芳基部分的化合物
CN102459251B (zh) * 2009-05-14 2015-05-20 詹森药业有限公司 作为白三烯a4水解酶的调节剂的具有两个稠合双环杂芳基部分的化合物
CN107663192A (zh) * 2017-11-03 2018-02-06 梯尔希（南京）药物研发有限公司 一种雷贝拉唑杂质的制备方法
CN107663192B (zh) * 2017-11-03 2019-05-10 梯尔希（南京）药物研发有限公司 一种雷贝拉唑杂质的制备方法
CN113735798A (zh) * 2021-09-27 2021-12-03 安徽美致诚药业有限公司 一种盐酸罗沙替丁醋酸酯的制备方法

Also Published As

Publication number Publication date
ATE405562T1 (de) 2008-09-15
KR101149379B1 (ko) 2012-06-28
IL173372A (en) 2010-11-30
SG130192A1 (en) 2007-03-20
HRP20060039A2 (en) 2006-08-31
PT1660492E (pt) 2008-11-13
NO20060771L (no) 2006-04-21
AR045729A1 (es) 2005-11-09
CA2534212A1 (en) 2005-02-10
HK1092790A1 (en) 2007-02-16
CN1860117A (zh) 2006-11-08
PL1660492T3 (pl) 2009-01-30
EP1660492A1 (en) 2006-05-31
RU2359970C2 (ru) 2009-06-27
US20050043379A1 (en) 2005-02-24
TW200520756A (en) 2005-07-01
HRP20060041B1 (hr) 2014-06-06
JP4726238B2 (ja) 2011-07-20
SI1660492T1 (sl) 2009-02-28
ES2313079T3 (es) 2009-03-01
HK1090359A1 (en) 2006-12-22
ZA200601716B (en) 2007-05-30
AU2004261628B2 (en) 2011-05-12
KR20060054408A (ko) 2006-05-22
BRPI0413072A (pt) 2006-10-03
UA82888C2 (en) 2008-05-26
SI1660491T1 (sl) 2009-02-28
ZA200601720B (en) 2007-11-28
NO20060823L (no) 2006-03-15
DE602004015620D1 (de) 2008-09-18
KR20060057593A (ko) 2006-05-26
AU2004261610B2 (en) 2010-05-20
SG129449A1 (en) 2007-02-26
CA2534228A1 (en) 2005-02-10
NZ544970A (en) 2009-02-28
AR045730A1 (es) 2005-11-09
AU2004261610A1 (en) 2005-02-10
CN100591679C (zh) 2010-02-24
DK1660491T3 (da) 2008-11-10
PL1660491T3 (pl) 2009-01-30
RU2006102510A (ru) 2006-07-27
WO2005012297A1 (en) 2005-02-10
DE602004016002D1 (de) 2008-10-02
ES2311858T3 (es) 2009-02-16
EP1660492B1 (en) 2008-08-20
DK1660492T3 (da) 2008-11-03
RU2006102508A (ru) 2006-07-27
PT1660491E (pt) 2008-10-10
ATE403654T1 (de) 2008-08-15
TWI362383B (en) 2012-04-21
JP2007500703A (ja) 2007-01-18
UA87986C2 (uk) 2009-09-10
WO2005012296A1 (en) 2005-02-10
IL173372A0 (en) 2006-06-11
NZ544938A (en) 2009-05-31
RU2373204C2 (ru) 2009-11-20
HRP20060041A2 (en) 2006-11-30
CY1108560T1 (el) 2014-04-09
EP1660491B1 (en) 2008-08-06
BRPI0412345A (pt) 2006-10-03
AU2004261628A1 (en) 2005-02-10
MY145080A (en) 2011-12-15
WO2005012297A9 (en) 2007-01-04
US20050043378A1 (en) 2005-02-24
TW200523255A (en) 2005-07-16
EP1660491A1 (en) 2006-05-31
JP2007500706A (ja) 2007-01-18

Similar Documents

Publication Publication Date Title
CN1856490A (zh) 苯并咪唑、苯并噻唑和苯并噁唑衍生物及其作为lta4h调节剂的应用
CN1229343C (zh) 趋化因子受体活性调节剂
CN1678586A (zh) 取代的喹啉ccr5受体拮抗剂
CN1305862C (zh) 作为腺苷受体配体的7－氨基苯并噻唑衍生物
CN1886380A (zh) 苯并咪唑化合物
US20080194630A1 (en) LTA4H modulators and uses thereof
CN1898221A (zh) Atp－结合弹夹转运蛋白的调控剂
CN1902171A (zh) 用作ccr－5拮抗剂的苄醚胺化合物
CN1845921A (zh) 金刚烷和氮杂双环－辛烷及壬烷衍生物、其制备方法及其作为dpp－iv抑制剂的用途
CN1032438A (zh) 新的取代的n-(1-烷基-3-羟基-4-哌啶基)苯甲酰胺
CN1642913A (zh) 用作趋化因子受体活性(尤其是ccr5)调节剂的哌啶或8－氮杂－二环[3.2.1]辛－3－基衍生物
CN1993358A (zh) 作为趋化因子受体拮抗剂的噻唑衍生物
CN1522250A (zh) 带有五元环基团的环状二胺化合物
CN1832745A (zh) 作为神经肽y5(npy5)配体用于治疗肥胖症的2－[4－(苯基氨基)－哌啶－1－基]－n－苯基－乙酰胺衍生物及相关化合物
CN1918139A (zh) 肉桂酰胺、肉桂酰胺的制备方法及包含肉桂酰胺的药物组合物
CN1100716A (zh) 碱性醚及其制备方法
CN1081677A (zh) 取代的苯基氨基甲酸酯和脲
MXPA06001122A (en) Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
HK1092790B (en) Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
MXPA06001121A (en) Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
HK1084666A (en) Triazole compounds useful in therapy
HK1099747A (en) Novel piperidine-substituted indoles- or hetero-derivatives thereof and their use as modulators of chemokine receptor (ccr-3)
HK1054930A1 (en) Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20061101

C20 Patent right or utility model deemed to be abandoned or is abandoned